Atorvastatin hemicalcium trihydrate is an orally activeHMG-CoAreductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion withIC₅₀s of 0.39 μM and 2.39 μM, respectively^[1][2][3].

Atorvastatin hemicalcium trihydrate treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation^[4].

Atorvastatin (20-30 mg/kg; oral gavage; once a day; for 28 days; ApoE^–/–mice) hemicalcium trihydrate treatment significantly reduces endoplasmic reticulum (ER) stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE-/- mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β are all remarkably inhibited after Atorvastatin treatment^[5].

632.73

C₃₃H₃₅FN₂O₅.1/2Ca.3H₂O

344920-08-7

阿托伐他汀半钙三水合物；阿托他伐汀半钙三水合物

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.